Management of Monitored Drug List Policy

Effective Date February 19, 2008

Initial Version: Approved by the Board of Directors on February 19, 2008
Revised Version: September 23, 2015

TABLE OF CONTENTS

NOVA SCOTIA PRESCRIPTION MONITORING PROGRAM

SECTION I

MANAGEMENT OF MONITORED DRUG LIST POLICY

---

1. Policy Objective

The purpose of this policy is to establish a process by which the list of monitored drugs is reviewed on a scheduled and consistent basis to ensure compliance with the Program's legislation.

2. Policy Statement

The Nova Scotia Prescription Monitoring Program is mandated through legislation to monitor the prescribing of certain drugs. The list of monitored drugs established in the July 2005 Regulations to the Prescription Monitoring Act includes any drugs that are controlled substances under the *Controlled Drugs and Substances Act* (Canada) and are listed in the schedules to the *Controlled Drugs and Substances Act* (Canada) or any successor legislation, except for testosterone (when dispensed as a compound for topical application for local effect) and drugs listed in Part 1 and 2 of Schedule 1 to the *Benzodiazepine and Other Targeted Substances Regulations* made under the *Controlled Drugs and Substances Act* (Canada).

The Board must ensure that the drugs designated under the regulations remain current over time. Operating in an evolving environment, the Board has a responsibility to confirm that the list of monitored drugs continues to comply with the *Controlled Drugs and Substances Act*, as well as the overall objectives established within the Prescription Monitoring Act.

3. Responsibilities

The Board is responsible to monitor the effectiveness of the processes put in place by the Administrator to manage the list of monitored drugs. The Board is also responsible to recommend changes to the Governor in Council to further the objects of the Program.

The Administrator is responsible for maintaining a current list of monitored drugs; implementing the guidelines included in this policy; operationalizing all approved changes to the monitored drug list; and, reporting to the Board on compliance with the policy.

4. Legislative Framework

The Prescription Monitoring Act specifies the following:

> *6 The Board shall*
> *(a) recommend drugs for designation by the Governor in Council as monitored drugs to further the objects of the Program;*

27 (1) The Governor in Council may make regulations
(c) designating drugs that are subject to the Program as monitored drugs;

The Regulations to the Prescription Monitoring Act state:

3 Any drug that is a controlled drug under the Controlled Drugs and Substances Act (Canada) and is listed in the Schedules to the Controlled Drugs and Substances Act (Canada) or any successor legislation is designated as being subject to the Program, except the following:
(a) testosterone, when dispensed as a compound for topical application for local effect;
(b) drugs listed in Part 1 and 2 of Schedule 1 to the Benzodiazepine and Other Targeted Substances Regulations made under the Controlled Drugs and Substances Act (Canada).

5. Principles

The following principles will guide the Board's oversight of this policy:

(a) The process for reviewing and revising the list of monitored drugs is developed by the Administrator and approved by the Board.

(b) The approved process is implemented by the Administrator and monitored by the Board.

(c) The Board recommends changes arising from the process to the Governor in Council.

(d) The Administrator implements all approved changes to the monitored drug list.

6. Definitions

In this policy:

(a) "Administrator" means the agency or person designated by the Minister to administer the Program, and for the purposes of this policy includes the Manager appointed by the Administrator or any other person employed by the Administrator.

(b) "Board" means the Nova Scotia Prescription Monitoring Board established by the Prescription Monitoring Act.

(c) "Medical Consultant" means a physician contracted by the Administrator to provide the Program with operational content expertise.

(d) "Monitored Drugs", per the Regulations to the Prescription Monitoring Act, means controlled substances under the *Controlled Drugs and Substances Act* (Canada) listed in the schedules to the *Controlled Drugs and Substances Act* (Canada) or any successor legislation, except for testosterone (when dispensed as a compound for topical application for local effect to the vaginal area) and drugs listed in Part 1 and 2 of Schedule 1 to the *Benzodiazepine and Other Targeted Substances Regulations* made under the *Controlled Drugs and Substances Act* (Canada).

"Monitored Drugs", per the Drug Information System Prescription Monitoring Regulations, means any drug that is a controlled drug under the Controlled Drugs and Substances Act (Canada) and is listed in the Schedules to the Controlled Drugs and Substances Act (Canada) or any successor legislation is designated as being subject to the Program.

(e) "Program" means the Prescription Monitoring Program established by the Board.

7. Scope

This section is to provide an indication of what and/or who particularly the policy applies to within the Prescription Monitoring Program Operations.

(a) the Board;

(b) Consultants contracted by the Program;

(c) the Administrator.

8. Accountability

The Administrator and Board Chair have the responsibility for the ongoing monitoring and enforcement of this policy.

9. Challenging Compliance

Any challenge to the Program's compliance with this policy shall be provided in writing to the Board Chair.

NOVA SCOTIA PRESCRIPTION MONITORING PROGRAM

SECTION II

GUIDELINES

Process for Reviewing the Monitored Drug List

As per the Prescription Monitoring Act, Section 6(a) The Board shall recommend drugs for designation by the Governor in Council as monitored drugs to further the objects of the Program. Should the Board require an additional review of the monitored drug list it may appoint an ad hoc committee which will consist of (at a minimum):

a) a pharmacist;
b) a prescriber;
c) the Program's Medical Consultant;
d) an outside consultant with addictions and/or pain management expertise.

Following a review by the ad hoc committee, a report will be submitted to the Board outlining opinions regarding the appropriateness of the current list of monitored drugs and recommendations for changes to the list.

The Board will review this information and determine if further action is warranted.

Process for Updating the Monitored Drug List

The list of monitored drugs is updated as new drugs are added to the applicable Schedules to the Controlled Drugs and Substances Act. The Drug Management department within Medavie Blue Cross is responsible for providing notification to the Program via email of any new or deleted CDSA drugs.

As well, the Board may confirm the addition of a non CDSA drug in situations where there is the potential for misuse and/or abuse. In the event that a non CDSA drug becomes designated as an NSPMP monitored drug, the Administrator will submit a request to the Drug Management department to add the product(s) to the NSPMP Benefit list. As new drugs are added to the NSPMP Benefit list, the Administrator will automatically update the "Drugs Requiring the Use of a Duplicate Prescription" list.

The Administrator will ensure the updated "Drugs Requiring the Use of a Duplicate Prescription" list is posted on the PMP website.